MedTrace Logo

A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks

NCT07469709 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 850

Last updated 2026-03-13

No results posted yet for this study

Summary

The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before the clinical and radiological manifestation of the disease. It starts with risk prediction and leads to early diagnosis of the disease or recurrence in the subclinical phase.

The PRO-ACTIVE study includes the following activities:

* WP1: Integrated DNA-RNA approach for the identification of hereditary markers of predisposition to tumors
* WP2: Global biological and molecular analysis of the host and tumor for the prevention and monitoring of recurrences
* WP3: Analysis of the immunological status for the diagnosis of primary prevention and relapses in correlation to genetic and environmental factors
* WP4: Study of the tumor microenvironment for recurrence prediction

Conditions

  • Breast Cancer
  • Colo-rectal Cancer
  • Ovarian Cancer
  • Melanoma (Skin Cancer)
  • Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)

Sponsors & Collaborators

  • Fondazione del Piemonte per l'Oncologia

    lead OTHER

Principal Investigators

  • Chiara Lazzari, MD · Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo

  • Federico Bussolino, MD · Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo

  • Luigia Pace, PhD · Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2027-05-01
Completion
2027-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07469709 on ClinicalTrials.gov